Diffusion Histogram Profiles Predict Molecular Features of Grade 4 in Histologically Lower-grade Adult Diffuse Gliomas Following WHO Classification 2021

Overview

Journal Eur Radiol

Specialty Radiology

Date 2023 Aug 15

PMID 37581661

Authors

Ryo Kurokawa

Akifumi Hagiwara

Mariko Kurokawa

Benjamin M Ellingson

Akira Baba

Toshio Moritani

Affiliations

Soon will be listed here.

Abstract

Objectives: In the latest World Health Organization classification 2021, grade 4 adult diffuse gliomas can be diagnosed with several molecular features even without histological evidence of necrosis or microvascular proliferation. We aimed to explore whole tumor histogram-derived apparent diffusion coefficient (ADC) histogram profiles for differentiating between the presence (Mol-4) and absence (Mol-2/3) of grade 4 molecular features in histologically lower-grade gliomas.

Methods: Between June 2019 and October 2022, 184 adult patients with diffuse gliomas underwent MRI. After excluding 121 patients, 18 (median age, 64.5 [range, 37-84 years]) Mol-4 and 45 (median 40 [range, 18-73] years) Mol-2/3 patients with histologically lower-grade gliomas were enrolled. Whole tumor volume-of-interest-derived ADC histogram profiles were calculated and compared between the two groups. Stepwise logistic regression analysis with Akaike's information criterion using the ADC histogram profiles with p values < 0.01 and age at diagnosis was used to identify independent variables for predicting the Mol-4 group.

Results: The 90th percentile (p < 0.001), median (p < 0.001), mean (p < 0.001), 10th percentile (p = 0.014), and entropy (p < 0.001) of normalized ADC were lower, and kurtosis (p < 0.001) and skewness (p = 0.046) were higher in the Mol-4 group than in the Mol-2/3 group. Multivariate logistic regression analysis revealed that the entropy of normalized ADC and age at diagnosis were independent predictive parameters for the Mol-4 group with an area under the curve of 0.92.

Conclusion: ADC histogram profiles may be promising preoperative imaging biomarkers to predict molecular grade 4 among histologically lower-grade adult diffuse gliomas.

Clinical Relevance Statement: This study highlighted the diagnostic usefulness of ADC histogram profiles to differentiate histologically lower grade adult diffuse gliomas with the presence of molecular grade 4 features and those without.

Key Points: • ADC histogram profiles to predict molecular CNS WHO grade 4 status among histologically lower-grade adult diffuse gliomas were evaluated. • Entropy of ADC and age were independent predictive parameters for molecular grade 4 status. • ADC histogram analysis is useful for predicting molecular grade 4 among histologically lower-grade gliomas.

Citing Articles

Correlation Analysis of Apparent Diffusion Coefficient Histogram Parameters and Clinicopathologic Features for Prognosis Prediction in Uveal Melanoma.

Zheng Y, Tang Y, Yao Y, Ge T, Pan H, Cui J Invest Ophthalmol Vis Sci. 2024; 65(8):3.

PMID: 38953846 PMC: 11221615. DOI: 10.1167/iovs.65.8.3.

T2-FLAIR Mismatch Sign Predicts DNA Methylation Subclass and CDKN2A/B Status in IDH-Mutant Astrocytomas.

Lee M, Jain R, Galbraith K, Chen A, Lieberman E, Patel S Clin Cancer Res. 2024; 30(16):3512-3519.

PMID: 38829583 PMC: 11326959. DOI: 10.1158/1078-0432.CCR-24-0311.

References

Ostrom Q, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan J . CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. Neuro Oncol. 2021; 23(12 Suppl 2):iii1-iii105. PMC: 8491279. DOI: 10.1093/neuonc/noab200. View

Ostrom Q, Bauchet L, Davis F, Deltour I, Fisher J, Langer C . The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol. 2014; 16(7):896-913. PMC: 4057143. DOI: 10.1093/neuonc/nou087. View

Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn J, Minniti G . EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2020; 18(3):170-186. PMC: 7904519. DOI: 10.1038/s41571-020-00447-z. View

Louis D, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee W . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6):803-20. DOI: 10.1007/s00401-016-1545-1. View

Louis D, Perry A, Wesseling P, Brat D, Cree I, Figarella-Branger D . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8):1231-1251. PMC: 8328013. DOI: 10.1093/neuonc/noab106. View

Gritsch S, Batchelor T, Gonzalez Castro L . Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system. Cancer. 2021; 128(1):47-58. DOI: 10.1002/cncr.33918. View

Roux A, Tran S, Edjlali M, Saffroy R, Tauziede-Espariat A, Zanello M . Prognostic relevance of adding MRI data to WHO 2016 and cIMPACT-NOW updates for diffuse astrocytic tumors in adults. Working toward the extended use of MRI data in integrated glioma diagnosis. Brain Pathol. 2020; 31(4):e12929. PMC: 8412115. DOI: 10.1111/bpa.12929. View

Nelson S, Cha S . Imaging glioblastoma multiforme. Cancer J. 2003; 9(2):134-45. DOI: 10.1097/00130404-200303000-00009. View

Brat D, Aldape K, Colman H, Holland E, Louis D, Jenkins R . cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". Acta Neuropathol. 2018; 136(5):805-810. PMC: 6204285. DOI: 10.1007/s00401-018-1913-0. View

10.

Brat D, Aldape K, Colman H, Figrarella-Branger D, Fuller G, Giannini C . cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol. 2020; 139(3):603-608. PMC: 8443062. DOI: 10.1007/s00401-020-02127-9. View

11.

Shirahata M, Ono T, Stichel D, Schrimpf D, Reuss D, Sahm F . Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathol. 2018; 136(1):153-166. DOI: 10.1007/s00401-018-1849-4. View

12.

Rezaei V, Rabiee A, Khademi F . Glioblastoma multiforme: a glance at advanced therapies based on nanotechnology. J Chemother. 2020; 32(3):107-117. DOI: 10.1080/1120009X.2020.1713508. View

13.

Yang K, Wu Z, Zhang H, Zhang N, Wu W, Wang Z . Glioma targeted therapy: insight into future of molecular approaches. Mol Cancer. 2022; 21(1):39. PMC: 8822752. DOI: 10.1186/s12943-022-01513-z. View

14.

Xie Y, Li S, Shen N, Gan T, Zhang S, Liu W . Assessment of Isocitrate Dehydrogenase 1 Genotype and Cell Proliferation in Gliomas Using Multiple Diffusion Magnetic Resonance Imaging. Front Neurosci. 2021; 15:783361. PMC: 8645648. DOI: 10.3389/fnins.2021.783361. View

15.

Gezer B, Mutlukan A, Sahinoglu M, Karabagli P, Koktekir E, Karabagli H . Comparison of Immunogenetic Properties of Glial Tumors with Advanced Magnetic Resonance Imaging Findings. Turk Neurosurg. 2020; 30(3):422-427. DOI: 10.5137/1019-5149.JTN.27261-19.3. View

16.

Liu T, Cheng G, Kang X, Xi Y, Zhu Y, Wang K . Noninvasively evaluating the grading and IDH1 mutation status of diffuse gliomas by three-dimensional pseudo-continuous arterial spin labeling and diffusion-weighted imaging. Neuroradiology. 2018; 60(7):693-702. DOI: 10.1007/s00234-018-2021-5. View

17.

Leu K, Ott G, Lai A, Nghiemphu P, Pope W, Yong W . Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas. J Neurooncol. 2017; 134(1):177-188. PMC: 7927357. DOI: 10.1007/s11060-017-2506-9. View

18.

Mesny E, Barritault M, Izquierdo C, Poncet D, DHombres A, Guyotat J . Gyriform infiltration as imaging biomarker for molecular glioblastomas. J Neurooncol. 2022; 157(3):511-521. DOI: 10.1007/s11060-022-03995-9. View

19.

Hagiwara A, Oughourlian T, Cho N, Schlossman J, Wang C, Yao J . Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors. Neuro Oncol. 2021; 24(6):1020-1028. PMC: 9159421. DOI: 10.1093/neuonc/noab276. View

20.

Ellingson B, Kim H, Woodworth D, Pope W, Cloughesy J, Harris R . Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology. 2014; 271(1):200-10. PMC: 4263651. DOI: 10.1148/radiol.13131305. View